Details for New Drug Application (NDA): 207947
✉ Email this page to a colleague
NDA 207947 describes UPTRAVI, which is a drug marketed by Actelion and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the UPTRAVI profile page.
The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the selexipag profile page.
The generic ingredient in UPTRAVI is selexipag. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the selexipag profile page.
Pharmacology for NDA: 207947
| Mechanism of Action | Prostacyclin Receptor Agonists |
Suppliers and Packaging for NDA: 207947
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| UPTRAVI | selexipag | TABLET;ORAL | 207947 | NDA | Actelion Pharmaceuticals US, Inc. | 66215-602 | 66215-602-06 | 1 BOTTLE in 1 CARTON (66215-602-06) / 60 TABLET, COATED in 1 BOTTLE |
| UPTRAVI | selexipag | TABLET;ORAL | 207947 | NDA | Actelion Pharmaceuticals US, Inc. | 66215-602 | 66215-602-14 | 1 BOTTLE in 1 CARTON (66215-602-14) / 140 TABLET, COATED in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 0.2MG | ||||
| Approval Date: | Dec 21, 2015 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 1, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 1, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Oct 31, 2026 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | ||||||||
Complete Access Available with Subscription
